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The study of left atrial (LA) ﬁbrosis with delayed enhance-
ment–magnetic resonance imaging (DE-MRI) is an estab-
lished technique that provides a noninvasive means of
detecting the electroanatomic substrate of atrial ﬁbrillation
(AF).1 We present a case of a middle-aged woman with
systemic lupus erythematosus (SLE) and persistent AF who
had extensive atrial ﬁbrosis as detected by DE-MRI before
the ablation procedure.Case Report
In October 2010, a 46-year-old woman was admitted to our
cardiology department for an ablation procedure of symp-
tomatic persistent AF. She had SLE since 1990, which
started as articular and then became renal involvement
(diffuse proliferative glomerulonephritis, class IV) and was
treated with steroid therapy, cyclosporine, and cyclophos-
phamide bolus. All therapies were discontinued in 2006
because of a complete remission of the disease. No
cardiovascular risk factor was present, in particular no
family history of cardiomyopathy. She was symptomatic
for impaired functional status, and she was refractory to
pharmacological treatment with antiarrhythmic drugs of
class 1C. The echocardiogram revealed normal dimensions
of the left ventricle with overall normal systolic function.
The LA was moderately enlarged, and the right atrium
was only slightly enlarged. Mild mitral regurgitation was
found.
Before the ablation procedure, she underwent MRI
with atrial ﬁbrosis detection (DE-MRI), as reported pre-
viously.1 DE-MRI was performed with a 1.5-T scannerKEYWORDS Atrial ﬁbrillation; Atrial ﬁbrosis; Systemic lupus erythematosus;
Magnetic resonance imaging
ABBREVIATIONS 3D ¼ 3-dimensional; AF ¼ atrial fibrillation; DE-MRI ¼
delayed enhancement–magnetic resonance imaging; LA ¼ left atrium/
atrial; SLE ¼ systemic lupus erythematosus
(Heart Rhythm Case Reports 2015;1:206–208)
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).(MAGNETOM Avanto, Siemens Medical Systems, Erlan-
gen, Germany) 15 minutes after a bolus injection of
0.1 mmol/kg of gadobenate dimeglumine (MultiHance,
Bracco Spa, Milan, Italy) using a 3-dimensional (3D)
inversion recovery prepared, respiration navigated, ECG-
gated, gradient echo pulse sequence with fat saturation
(Gradient Echo 3-dimensional Inversion Recover Turbo
Flash). The axial DE-MRI images revealed massive
delayed enhancement in different regions of the LA (see
the Online Video), including anterior wall (Figure 1A),
posterior wall, and septum (Figure 1B). The percentage of
ﬁbrosis relative to the volume of the LA wall2 was 40%.
Furthermore, a signiﬁcant homogeneous thickening distri-
bution of the atrial wall was present (measured thickness
6.8 mm). The maximum LA volume and LA emptying
fraction3 were 38 ml/mq and 47%, respectively. The DE
imaging performed using a 2D inversion recovery sequence
after contrast injection demonstrated a small area of ﬁbrosis
in the inferolateral mid-wall ventricular myocardium.
During the electrophysiological study (CARTO3, Bio-
sense Webster, Inc., Diamond Bar, CA), the endocardial
electroanatomic map of the LA conﬁrmed large areas of low
bipolar voltage (o0.05 mV) in the anterior wall and septum
(Figure 1C) and an area of electrically abnormal tissue (0.05
mVo bipolar voltageo1 mV) in the posterior wall and roof
(Figure 1D). The percentage of ﬁbrosis relative to the LA
surface estimated by using the CARTO3 system was 52%.
The ablation procedure was performed without compli-
cations; nevertheless, during follow-up, the patient had
recurrences of atrial tachycardia.
SLE is an inﬂammatory autoimmune disease that can
virtually affect all organ systems.4 Cardiovascular involvement
occurs frequently (58%–77%).5 The most common cardiac
manifestations include pericarditis (25% of all patients with
SLE),6,7 myocarditis,8 coronary artery disease,9 valvular lesion
such as valvular thickening and regurgitation, and Libman-
Sacks endocarditis (prevalence 11%–74%).10 In the context of
cardiac arrhythmias, sinus tachycardia (50% of patients), AF,
and atrial ectopic beats are the most frequent.11 All types of
atrioventricular blocks, intraventricular conduction disturban-
ces, and sick sinus syndrome are also observed.12,13pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.02.014
KEY TEACHING POINTS
 Extensive atrial ﬁbrosis was detected by delayed
enhancement–magnetic resonance imaging in a
patient with systemic lupus erythematosus and
atrial ﬁbrillation with no other cardiovascular risk
factors. To our knowledge, atrial ﬁbrosis has not
been previously reported in systemic lupus
erythematosus or in other autoimmune diseases.
 The presence of an uncommon thickening of the
left atrial wall is frequently found in storage
disorders such as amyloidosis. Delayed
enhancement–magnetic resonance imaging helps
to make a differential diagnosis.
 The reduced atrial functionality could be
interpreted as a predictor of cardiovascular events.
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manifestations in SLE.6 Histological features of SLE car-
diomyopathy include initially inﬂammatory cell inﬁltrates
and, as the disease advances, myocardial necrosis, ﬁbrotic
replacement, and scarring.14,15 Cases of intramural and
subepicardial ventricular ﬁbrosis detected by DE-MRI have
been described in the literature.14 In addition, in other
inﬂammatory autoimmune and vasculitic diseases, DE-
MRI most frequently detected a midwall ventricular ﬁbrosis,Figure 1 Two-dimensional slice from the delayed enhancement–magnetic reson
and posterior (B) walls of the left atrium. An electroanatomic map shows large patc
interspersed with electrically abnormal tissue (0.0 5 mV o bipolar voltageo1 mprobably owing to a combination of subclinical inﬂammatory
and immunological processes,16 while a mosaic patchy
distribution of myocardial ﬁbrosis is a pathognomonic feature
of systemic sclerosis17 and recently all ventricular patterns
(subendocardial, subepicardial, intramural, and transmural)
are observed in these diseases.18 Nevertheless, to of our
knowledge, atrial ﬁbrosis has not been previously reported in
SLE or other autoimmune diseases. However, the study of
atrial ﬁbrosis using DE-MRI is recent and not widely
implemented in the clinical setting of patients with AF.
Herein, we also highlight the following peculiar features
of this case:1.anc
hes
V)The occasional feedback of a signiﬁcant thickening of the
atrial wall in a patient with SLE and AF, a ﬁnding of DE-
MRI that is frequently detected in storage disorders, such
as amyloidosis, that have a known etiopathogenetic
mechanism. DE-MRI helped us make a differential
diagnosis between these abnormalities.2. The extension of atrial ﬁbrosis by at least 40% compared
to the volume of the LA wall, as evidenced by DE-MRI. It
is known that atrial ﬁbrosis with an increase in extrac-
ellular matrix deposition results in intra-atrial conduction
disturbances (ie, anisotropy and zigzag conduction), thus
creating a substrate for AF.19,20
These ﬁndings are matched to a given reduced atrial
functionality that could be interpreted as a predictor of
cardiovascular events.3,21,22e imaging scan shows massive delayed enhancement in the anterior (A)
of low bipolar voltage (o0.05 mV) in the anterior wall and septum (C),
in the posterior wall and roof (D).
Heart Rhythm Case Reports, Vol 1, No 4, July 2015208In conclusion, in a patient with SLE with no other
cardiovascular risk factors, the presence of an uncommon
thickening of the LA wall associated with an extensive atrial
ﬁbrosis could, in our opinion, justify the refractoriness of
AF. The important question that needs to be answered is
whether SLE leads to atrial ﬁbrosis, and other studies are
necessary to conﬁrm a correlation between them.
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